Trials / Completed
CompletedNCT04761900
MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes
Metabolic Associated Fatty Liver Disease-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes in Real World
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,372 (actual)
- Sponsor
- Ningbo No. 1 Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- —
Summary
Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries.
Detailed description
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. It affects nearly 25% of the global population. Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries. It may provide a better understanding of MAFLD, and optimize strategies for prevention of extrahepatic complications in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
- First posted
- 2021-02-21
- Last updated
- 2021-02-21
Source: ClinicalTrials.gov record NCT04761900. Inclusion in this directory is not an endorsement.